engleski

Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas – a pilot study

BORIS is a paralog of a highly conserved, multi- functional chromatin factor CTCF. Unlike CTCF, which has been shown to possess tumor-suppressive properties, BORIS belongs to the “cancer/testis antigen” family normally expressed only in germ cells and aberrantly activated in a variety of tumors. The consequences of BORIS expression, relative abundance of its isoforms and its role in carcinogenesis have not been completely elucidated. It activates transcription of hTERT and MYC, genes relevant for laryngeal carcinoma progression. In this study, BORIS expression has been analyzed at transcriptional level by RT-PCR and protein level by semi-quantitative immunohistochemistry in 32 laryngeal squamous cell carcinomas and adjacent non-tumorous tissue. BORIS has been detected in 44% (14/32) laryngeal squamous cell carcinoma samples, while it has been detected only in one normal, tumor-adjacent tissue sample. Survival analysis, using recursive partitioning algorithm mvpart, has extracted the ratio of relative abundance of BORIS transcript variants containing exon 7 (BORIS 7+) and those lacking exon 7 (BORIS 7-) as an independent prognostic factor associated with the disease relapse during 5-years follow-up period. Patients having BORIS 7+/BORIS 7- ratio ≥1 had higher rate of disease relapse than patients with BORIS 7+/BORIS 7- ratio <1. Hazard ratio for that group, based on Cox Proportional Hazard Regression, was 3.53. This is the first study analyzing expression of BORIS protein and transcript variants in laryngeal squamous cell carcinoma relative to its possible prognostic value for recurrence and overall survival.

laryngeal squamous cell carcinoma; BORIS; transcript variant; immunohistochemistry; RT-PCR

nije evidentirano